Product List PHA
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Molecular Cloning of an O-Methyltransferase from Adventitious Roots of Carapichea Ipecacuanha
100605 (016) Biosci. Biotechnol. Biochem., 75 (1), 100605-1–7, 2011 Molecular Cloning of an O-Methyltransferase from Adventitious Roots of Carapichea ipecacuanha y Bo Eng CHEONG,1 Tomoya TAKEMURA,1 Kayo YOSHIMATSU,2 and Fumihiko SATO1; 1Division of Integrated Life Science, Graduate School of Biostudies, Kyoto University, Oiwake-cho, Kitashirakawa, Sakyo-ku, Kyoto 606-8502, Japan 2Research Center for Medicinal Plant Resources, National Institute of Biomedical Innovation, 1-2 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan Received August 20, 2010; Accepted October 5, 2010; Online Publication, January 7, 2011 [doi:10.1271/bbb.100605] Carapichea ipecacuanha produces various emetine- industrial production.2) Whereas metabolic engineering type alkaloids, known as ipecac alkaloids, which have in alkaloid biosynthesis has also been explored to long been used as expectorants, emetics, and amebicides. improve both the quantity and the quality of several In this study, we isolated an O-methyltransferase cDNA alkaloids,3) biosynthetic enzymes and their genes in from this medicinal plant. The encoded protein ipecac alkaloids are still limited, except for the recent (CiOMT1) showed 98% sequence identity to IpeOMT2, isolation of glycosidases and O-methyltransferases.4,5) which catalyzes the 70-O-methylation of 70-O-demethyl- Ipecac alkaloids are synthesized from the condensa- cephaeline to form cephaeline at the penultimate step tion of dopamine derived from tyrosine, for isoquinoline ofAdvance emetine biosynthesis (Nomura and Kutchan, ViewJ. Biol. moieties, and from secologanin, as a monoterpenoid Chem., 285, 7722–7738 (2010)). Recombinant CiOMT1 molecule (Fig. 1). This Pictet-Spengler-type condensa- showed both 70-O-methylation and 60-O-methylation tion yields two epimers, (R)-N-deacetylipecoside and activities at the last two steps of emetine biosynthesis. -
O SIEMSGLUSS IBERICA, S.A
SIEMSGLUSS IBERICA, S.A. Product list G Memantine HCI Propylparaben Sodium Pharma APls Gemfibrozil Mepiramina Maleato R Gentian Powder Methoxsalen Ramipril Gentian Violet Methyl Nicotinate Ranitidin HCI Glibenclamide Methylprednisolone Base Rapamycin (Slrollrnus) Glimepiride Metimazole Resorcin A e Gluthatione reduced Metronidazol Resveratrol (Veri-Te®) 11 Alpha Hydroxyprogesterone Caffein Anhydrous Cyproterone Acetate Guaiacol Glyceril Ether Mexiletine HcI Rifampicin 17 Alpha Estradiol Calcipotriol Mieonazole Nitrate o H Roxythromycin Acetyl Salicylic Acid Canrenone Miltefosine Desonide Micronized Hydroquinone AcetylSpiramycin Cantharidin Minocycline HcI Dexamethasone BaseMicro Hyaluronic Acid Sodium Salt s Adapalene Captopril Minoxidil Seenidazol Dexamethasone Isonicotinate Miero Hydrochlorthiazide Amidopyrine Carbamazepine Mometasone Furoato Silver Sulfadiazine Dexamethasone Sodium Phosphate Hydrocortisone Acetate Micro Amikacin Sulphate Carbidopa Montelukast Sodium Simvastatine Dexketoprofen Trometamol Hydrocortisone BaseMicro Amiloride Carisoprodol Sodium Cefonicide Dextrometorphan Bromhidrate Hydroxyzine HcI N Amitriptyline HCI Carvedilol $pironolactone Micro Dextrose (Glucosa) Anhydrous N Aeetyl Glueosamine Amoxlcillin Na + Clavulonate K Cefaclor Monohidrate Sulpiride Diacethyl Naproxen Powder Ibuprofen Amoxicillin Na + Clavulonate K(5:1) Cefadroxil Compaeted Dielofenae Sodium Neutral Pellets Idebenone T Amoxicillin Trihydrate Compacted Cefalexine Monohydrate Powder Difenhydramire Nisin Taerollmus Monohydrate Imiquimod Amoxlcillln -
RIEMSER Group International Product List
RIEMSER Group International Product List Product Active substance Presentation Indication Product Category Channel EMB Fatol Ethambutol • POI 1g/10ml Treatment of several forms and stages of Anti-infectives Rx dihydrochloride • TAB 100mg tuberculosis • FCT 400, 500 mg Eremfat Rifampicin • GRA 1.2g/60ml Anti-infectives Rx • POI 300, 600mg Tuberculosis therapy , combination treatment of • FCT 150, 300, 450, 600 leprosy, prophylaxis for meningococcal meningitis, treatment of infections caused by nontuberculous mycobacteria Isozid Isoniazid • TAB 50, 100, 200 mg During Chemotherapy, -prophylaxis and - Anti-infectives Rx • POI 500mg prevention for / of tuberculosis Isozidcomp Isoniazid / pyridoxine • TAB 100mg / 20mg Chemotherapy, -prophylaxis and -prevention for / Anti-infectives Rx • FCT 200mg /40 mg, 300mg/60mg of Tuberculosis PAS-Fatol Sodium aminosalicylate • POI 13.49g Chemotherapy for tuberculosis, caused by Anti-infectives Rx dihydrate mycobacterium tuberculosis and mycobacterium bovis. Peteha Protionamide • FCT 250mg Treatment of tuberculosis, leprosy and diseases Anti-infectives Rx caused by so-called ubiquitours (atypical) mycobacteria Pyrafat Pyrazinamide • FCT 500mg Combination therapy for all types of tuberculosis, Anti-infectives Rx • TAB 500mg caused by mycobacterium tuberculosis, mycobacterium africanum, or mycobacterium microtti. Terizidon Terizidone • CAP 250mg Treatment of tuberculosis caused by Anti-infectives Rx mycobacterium tuberculosis Vancomycin Enterocaps Vancomycin • CAP 250 mg Treatment of certain types of bowel -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Postprint: International Journal of Food Science and Technology 2019, 54
1 Postprint: International Journal of Food Science and Technology 2019, 54, 2 1566–1575 3 Polyphenols bioaccessibility and bioavailability assessment in ipecac infusion using a 4 combined assay of simulated in vitro digestion and Caco-2 cell model. 5 6 Takoua Ben Hlel a,b,*, Thays Borges c, Ascensión Rueda d, Issam Smaali a, M. Nejib Marzouki 7 a and Isabel Seiquer c 8 aLIP-MB laboratory (LR11ES24), National Institute of Applied Sciences and Technology, 9 Centre urbain nord de Tunis, B.P. 676 Cedex Tunis – 1080, University of Carthage, Tunisia. 10 bDepartment of Biology, Faculty of Tunis, University of Tunis El Manar, 11 Tunis, Tunisia 12 cDepartment of Physiology and Biochemistry of Animal Nutrition, Estación Experimental del 13 Zaidín (CSIC), Camino del Jueves s/n, 18100 Armilla, Granada, Spain. 14 dInstitute of Nutrition and Food Technology José Mataix Verdú, Avenida del Conocimiento 15 s/n. Parque Tecnológico de la Salud, 18071 Armilla., Granada, Spain. 16 17 * Corresponding author: Takoua Ben Hlel. E-mail: [email protected]. Tel.: +216 18 53 831 961 19 Running title : Antioxidant potential of Ipecac infusion 20 1 21 Abstract: 22 In this report, we investigated for the first time the total polyphenols content (TPC) and 23 antioxidant activity before and after digestion of Carapichea ipecacuanha root infusion, 24 better known as ipecac, prepared at different concentrations. An in vitro digestion system 25 coupled to a Caco-2 cell model was applied to study the bioavailability of antioxidant 26 compounds. The ability of ipecac bioaccessible fractions to inhibit reactive oxygen species 27 (ROS) generation at cellular level was also evaluated. -
EAR, NOSE and OROPHARYNX Updated: October 2020
Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief. -
HEALTHY ENVIRONMENTS a Compilation of Substances Linked to Asthma
HEALTHY ENVIRONMENTS A Compilation of Substances Linked to Asthma Prepared by Perkins+Will for the National Institutes of Health, Division of Environmental Protection, as part of a larger effort to promote health in the built environment. July 2011 PURPOSE STATEMENT This report was prepared by Perkins+Will on behalf of the National Institutes of Health, Office of Research Facilities, Division of Environmental Protection, as part of a larger effort to promote health in the built environment. Our research team noted that based on extensive experience, there is a need for more research on the impact that materials and conditions in the built environment have on occupant health. Additionally, existing research data has not been compiled and made available in a form that is readily usable by building professionals for integrating health protective features in the design and construction of buildings. Toward meeting these needs our research team set out to compile data on substances in the built environment that may cause or aggravate asthma, a disease of high and increasing prevalence and major economic importance. This list should be a valuable resource for identifying asthma triggers and asthmagens, minimizing their use in building materials and furnishings, and contributing to our larger goals of fostering healthier built environments. HEALTHY ENVIRONMENTS CONTENTS 02 Purpose Statement 04 Executive Summary 05 Defining Asthma 06 Asthma in the Global Context 07 Cost of Asthma 08 Framing the Issue 10 Asthma Triggers and Asthmagens 10 Development -
Ear, Nose and Oral Cavity
NHS Borders Joint Prescribing Formulary Ear, nose, and oral cavity Black Text Drugs which may be prescribed by all prescribers Drugs which are either for specialist only prescription or for specialist Pink Text initiation, with prescribing transfer to GP Important Information: In addition to the disclaimer on NHS Borders website the following information is included confirming that the information contained in NHS Borders Joint Prescribing formulary is drawn from several sources, including BNF & BNF for children, product SPCs, local and national guidelines, local expert opinion, Lothian Joint Formulary and these are all gratefully acknowledged here. NHS Borders has done its utmost to ensure the information in the BJF is accurate and reliable, but NHS Borders cannot guarantee that the information is complete and accurate. Prescribers are referred to the SPCs, BNF and BNF for children to confirm prescribing information. June 2021 Contents Page Table of Contents 12.1 Drugs acting on the ear ................................................................................................ 3 Otitis externa ................................................................................................................ 3 Otitis media .................................................................................................................. 3 Removal of ear wax ..................................................................................................... 3 12.2 Drugs acting on the nose ............................................................................................ -
The Breath of Life: Respiratory Function and Botanical Medicine
Applied Phytotherapeutics The Breath of Life: Respiration By Terry Willard ClH, PhD, Todd Caldecott ClH Session 3 The Breath of Life: Respiratory Function and Botanical Medicine Introduction We usually take one of the most fundamental and transformative elements of life for granted: breathing. Through the breath, we share air with all other humans and many forms of life on the planet; we form a oneness with the trees and other plant life through our symbiotic exchange of oxygen and carbon dioxide exchange relationship with them through the oxygen and carbon dioxide exchange. We breathe each other in! ©2019 Wild Rose College of Natural Healing All Rights Reserved. 1 Applied Phytotherapeutics The Breath of Life: Respiration By Terry Willard ClH, PhD, Todd Caldecott ClH Session 3 This connects us deeply with the ecology of the planet, as well as states of Being. Remember, the origin of the word “inspiration” comes from the concept of bringing the breath of spirit into you. Every time we breathe in, we not only bring air into our lungs but Prana as well. The two Lungs Hug our Heart with each Breath. Hugged by Prana. Breathing is primarily an autonomic process that most of us are unaware of until some stressor—be it strenuous exercise or the induction of fight or flight mechanisms—calls our attention to it. We especially become conscious of the act of breathing when we cannot breathe, for example when swimming or trapped underwater, or because of a disease such as asthma or anaphylaxis. Breath is our most immediate and vital form of nourishment, and from an Ayruvedic perspective, is synonymous with the flow of consciousness, and all activities of the body. -
Parallel Import (PI) Licences Granted in May 2017
Parallel import (PI) licences granted in May 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 15184/1699 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.25% W/V EYE DROPS SOLUTION TIMOLOL 2.5 MILLIGRAMMES PER MILLILITRE POM PLPI 15184/1700 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.5% W/V EYE DROPS SOLUTION TIMOLOL 0.5 MILLIGRAMMES PER MILLILITRE POM PLPI 16369/1716 03/05/2017 G-PHARMA LIMITED CELIPROLOL HYDROCHLORIDE 200MG TABLETS CELIPROLOL HYDROCHLORIDE 200.000 MILLIGRAMMES POM PLPI 21828/0717 03/05/2017 LANDMARK PHARMA LIMITED LEVOCARNITINE PAEDIATRIC 30% ORAL SOLUTION LEVOCARNITINE 30.00 PERCENT WEIGHT IN VOLUME POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED COLESTYRAMINE SUGAR FREE 4G-SACHET COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED QUESTRAN LIGHT 4G-SACHET POWDER FOR ORAL SUSPENSION COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER FLUTICASONE PROPIONATE 500.00 MICROGRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER SALMETEROL XINAFOATE 0.0725 MILLIGRAMMES POM PLPI 33532/0779 03/05/2017 MPT PHARMA LIMITED TRIMIPRAMINE 25MG FILM-COATED TABLETS TRIMIPRAMINE MALEATE 34.9 MILLIGRAMMES POM PLPI 39352/0376 03/05/2017 KOSEI PHARMA UK LIMITED DESMOPRESSIN ACETATE 0.1MG TABLETS DESMOPRESSIN ACETATE 0.1 MILLIGRAMMES POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION CLIOQUINOL -
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of -
Queensland Health List of Approved Medicines
Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.